Lab Med Qual Assur 2023; 45(2): 76-80
Published online June 30, 2023
Copyright © Korean Association of External Quality Assessment Service.
1Department of Laboratory Medicine, Veterans Health Service (VHS) Medical Center; 2Seegene Institute of Clinical Research, Seegene Inc., Seoul, Korea
Correspondence to:Misuk Ji
Department of Laboratory Medicine, Veterans Health Service Medical Center, 53 Jinhwangdo-ro 61-gil, Gangdong-gu, Seoul 05368, Korea
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Soluble suppression of tumorigenicity 2 (sST2) is a novel biomarker for heart failure (HF). It is known that the prevalence of HF increases with age. This study aimed to determine the reference intervals (RIs) of sST2 in South Koreans aged 60 years and above. From November 2018 to March 2019, serum sST2 levels were measured with the Presage ST2 enzyme-linked immunosorbent assay (Critical Diagnostics, USA) in 153 study participants (99 men and 54 women) with a mean age of 73.4±7.8 years. The median sST2 level was 32.9 ng/mL (interquartile range [IQR], 25.1–39.7 ng/mL) for men and 26.9 ng/mL (IQR, 23.5–34.4 ng/mL) for women. sST2 levels were higher in males than in females (P=0.0117). The central 95% RIs were 10.5–54.7 ng/mL for men and 9.1–46.7 ng/mL for women. The 97.5 percentile upper reference limits were higher in both sexes compared with those of the manufacturer and previous studies. The proportion of the study participants exceeding the cut-off of 35 ng/mL for HF was 33.1% (37 men and 10 women). One must exercise caution when interpreting the sST2 results in the elderly.
Keywords: Soluble suppression of tumorigenicity 2, Heart failure, Reference values, Aged
|View Full Text||PubReader|
|Abstract||Print this Article|
|E-mail alert||Export to Citation|
|Article as PDF||Open Access|